- Feb 14, 2020
- 1,630
- Tinnitus Since
- 1-2019
- Cause of Tinnitus
- 20+ Years of Live Music, Motorcycles, and Power Tools
Yes, they will wait. The strategy is almost outlined in their presentation. They compare the three trials to the patient populations affected.Would they necessarily wait for all of them to finish before starting to prep and recruit for Phase 3, though? And Phase 2 was delayed because of COVID-19 too, right?
My completely uneducated and optimistic guess is that they start injecting people for Phase 3 in late Q3 2021, read out 200 days later, and then like you say, market release in 2023, hopefully early.
By waiting for all three trials to end, they have data to confirm FX-322 is safe for mild-severe SNHL, NIHL, age-related SNHL.
This is a huge population for recruiting and allows them to designate the drug with the FDA in a single pivotal trial.
I would expect if they all look promising, Breakthrough Therapy status will happen in Q4/2021. Pivotal kicks off 2022.
They will certainly do an interim analysis of the Phase 3.